The influence of body mass index on the survival of patients with melanoma. A cross-sectional study of 707 patients

Zepeda-Najar, César; Lino‐Silva, Leonardo S.; Chávez-Hernández, Jazmín D; Salcedo‐Hernández, Rosa A.; Jimenez-Sánchez, Johana P.; Fernández-Sánchez, Carlos E.; Valdez-Aguilar, Carlos D.

doi:10.5114/wo.2021.104799

Cited by 3 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Kondo et al (2018) and Cortellini et al (2019) emphasized BMI’s prognostic importance in melanoma and other malignancies treated with ICIs [ 41 , 42 ]. Conversely, Rutkowski et al (2020), Deckers et al (2021), and Zepeda-Najar et al (2021) presented varied outcomes regarding obesity’s prognostic significance in melanoma [ 6 , 26 , 43 ]. Di Filippo et al (2021), Lee et al (2022), and Antoun et al (2023) nuanced this discussion by suggesting that BMI alone may not fully capture the impact of a patient’s body composition on prognosis, highlighting the importance of considering other factors such as skeletal muscle mass [ 44 , 45 , 46 ].…”

Section: Resultsmentioning

confidence: 99%

“…Nevertheless, the dynamics between BMI, treatment efficacy, and prognosis are complex. Variations in how BMI affects treatment outcomes indicate that the survival benefits associated with higher BMI might differ based on gender, type of treatment, and other variables [ 6 , 26 , 43 , 44 , 45 , 46 , 47 , 51 , 52 ]. Moreover, the counterintuitive nature of these results, where factors typically linked to negative health outcomes emerge as indicators of better survival and response to treatment, calls for a reassessment of BMI’s role in cancer metabolism and immunotherapy responses [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, Incorvaia et al (2023) investigated the response to immunotherapy, finding that pretreatment with low levels of soluble immune checkpoints accompanied by increased tumor-infiltrating lymphocytes can predict better outcomes in immunotherapy [25]. On the other hand, some patients with CM showed no response to ICIs [6,26]. Khojandi et al (2021) identified alternative pathways, such as oxidative stress and lipid metabolism, as mediators in the intricate connection between obesity and resistance to immunotherapy in melanoma, with oxidized low-density lipoproteins playing a pivotal role in supporting tumor cell survival.…”

Section: Obesity and Melanoma Biologymentioning

confidence: 99%

“…BMI ≥ 25 kg/m 2 2. BMI < 25 kg/m 2 BMI ≥ 25 kg/m 2 ➡ improved survival (OS, PFS), irAEs ⬆ Cortellini [38] Bastacky [39] An [10] BMI ≥ 25 kg/m 2 ➡ improved survival (OS, PFS) Nie [11] Zepeda-Najar [6] Antoun [46] McQuade [47] Rutkowski [26] No survival advantage Deckers [43] Di Filippo [44] Lee [45] Additionally, McQuade et al (2018) noted a gender-specific survival benefit for obese men receiving targeted and immune therapies [47]. Concurrently, epidemiological data show that men experience higher melanoma incidence and mortality rates compared to women [1,[48][49][50][51][52].…”

Section: Reference Bmi Cohorts Melanoma Prognosismentioning

confidence: 99%

“…These prognostic factors include Breslow thickness, mitotic rate, the presence of ulceration, age, sex, and anatomic location [ 1 , 2 , 3 ]. Intriguingly, recent studies have unveiled an apparent paradox: elevated body mass index (BMI) correlates with increased Breslow thickness, suggesting a dire prognosis [ 4 , 5 , 6 , 7 ]. Yet, paradoxically, it appears to enhance therapeutic responsiveness, a phenomenon not exclusive to CM but observed across various malignancies [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The Effect of Body Mass Index on Melanoma Biology, Immunotherapy Efficacy, and Clinical Outcomes: A Narrative Review

Jansen,

Garmyn,

Güvenç

2024

IJMS

View full text Add to dashboard Cite

Recent studies indicate that a higher body mass index (BMI) might correlate with improved responses to melanoma treatment, especially with immune checkpoint inhibitors (ICIs), despite the general association of obesity with an increased risk of cancer and higher mortality rates. This review examines the paradoxical relationship between BMI and clinical outcomes in melanoma patients by exploring molecular links, the efficacy of immunotherapy, and patient survival outcomes. Our comprehensive literature search across the PubMed and Embase databases revealed a consistent pattern: increased BMI is associated with a better prognosis in melanoma patients undergoing ICI treatment. This “obesity paradox” might be explained by the metabolic and immunological changes in obesity, which could enhance the effectiveness of immunotherapy in treating melanoma. The findings highlight the complexity of the interactions between obesity and melanoma, suggesting that adipose tissue may modulate the immune response and treatment sensitivity favorably. Our review highlights the need for personalized treatment strategies that consider the metabolic profiles of patients and calls for further research to validate BMI as a prognostic factor in clinical settings. This nuanced approach to the obesity paradox in melanoma could significantly impact treatment planning and patient management.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Obesity and Melanoma Biologymentioning

confidence: 99%

Section: Reference Bmi Cohorts Melanoma Prognosismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The Effect of Body Mass Index on Melanoma Biology, Immunotherapy Efficacy, and Clinical Outcomes: A Narrative Review

Jansen,

Garmyn,

Güvenç

2024

IJMS

View full text Add to dashboard Cite

show abstract

Thiazolidinedione enhances the efficacy of anti-PD-1 monoclonal antibody in murine melanoma

Zhang,

Gao,

Tang

et al. 2024

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

Several clinical studies observed a surprising beneficial effect of obesity to increase immunotherapy responsiveness in melanoma patients, highlighting an as-yet insufficiently understood relationship between metabolism and immunogenicity. Here we demonstrate that the thiazolidinedione (TZD) rosiglitazone, a drug used to treat diabetes by sequestering fatty acids in the metabolically inert subcutaneous adipose tissue, improved sensitivity to anti-Programmed Cell Death Protein 1 (PD-1) treatment in YUMMER1.7 tumor-bearing mice, a murine melanoma model that is initially sensitive to immunotherapy. We observed a transition from high to intermediate PD-1 expression in tumor-infiltrating CD8+ T cells. Moreover, we observed inhibited PD-1 expression in mouse and human T cells treated with TZD in vitro. In addition to its direct impact on immune cells, TZD also decreases circulating insulin concentrations, while insulin induced exhaustion in T cell culture. In TZD-treated mice, we observed higher fatty acid concentrations in the tumor microenvironment, with fatty acids protecting against exhaustion in culture. Together, these data are consistent with an indirect mechanism of TZD inhibiting T cell exhaustion. Finally, we analyzed imaging data from melanoma patients before and after anti-PD-1 treatment and confirmed a beneficial effect of increased subcutaneous fat on anti-PD-1 responsiveness in patients. We also found that the expression of PPARg, the canonical activator of lipid uptake and adipogenesis, which is activated by TZD, is correlated with overall survival time. Taken together, these data identify a new adjuvant to sensitize mice with YUMMER1.7 melanoma to immunotherapy, and discover a new metabolism-based prognostic marker in human melanoma.

show abstract

Somatotypological Parameters of the Body in Men With Benign Nevi

Haddad¹,

Матешук-Вацеба

Maievskyi

et al. 2022

WOMAB

View full text Add to dashboard Cite

The influence of body mass index on the survival of patients with melanoma. A cross-sectional study of 707 patients

Cited by 3 publications

References 16 publications

The Effect of Body Mass Index on Melanoma Biology, Immunotherapy Efficacy, and Clinical Outcomes: A Narrative Review

The Effect of Body Mass Index on Melanoma Biology, Immunotherapy Efficacy, and Clinical Outcomes: A Narrative Review

Thiazolidinedione enhances the efficacy of anti-PD-1 monoclonal antibody in murine melanoma

Somatotypological Parameters of the Body in Men With Benign Nevi

Contact Info

Product

Resources

About